Avid Bioservices (NASDAQ:CDMO) Earns Market Perform Rating from William Blair

William Blair restated their market perform rating on shares of Avid Bioservices (NASDAQ:CDMO) in a report issued on Tuesday morning, MarketBeat reports. William Blair also issued estimates for Avid Bioservices’ Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.03) EPS and Q4 2026 earnings at $0.01 EPS.

Separately, Royal Bank of Canada reiterated an outperform rating and set a $8.00 price target on shares of Avid Bioservices in a research note on Wednesday, July 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $13.50.

Avid Bioservices Stock Up 5.3 %

CDMO stock opened at $11.16 on Tuesday. The stock has a market capitalization of $709.56 million, a PE ratio of -5.05 and a beta of 1.37. Avid Bioservices has a 52 week low of $4.07 and a 52 week high of $11.57. The company has a quick ratio of 0.31, a current ratio of 0.46 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $9.89 and a 200 day moving average of $8.33.

Avid Bioservices (NASDAQ:CDMO) last posted its quarterly earnings results on Tuesday, July 2nd. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.10). The company had revenue of $42.98 million during the quarter, compared to analysts’ expectations of $42.60 million. Avid Bioservices had a negative return on equity of 11.27% and a negative net margin of 100.57%. Sell-side analysts forecast that Avid Bioservices will post -0.31 earnings per share for the current year.

Insider Buying and Selling at Avid Bioservices

In other news, CEO Nicholas Stewart Green sold 7,657 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $7.54, for a total value of $57,733.78. Following the completion of the transaction, the chief executive officer now owns 212,314 shares of the company’s stock, valued at approximately $1,600,847.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 9,216 shares of company stock valued at $69,984. 2.39% of the stock is owned by insiders.

Institutional Trading of Avid Bioservices

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new position in shares of Avid Bioservices in the second quarter worth about $38,000. Mather Group LLC. purchased a new position in shares of Avid Bioservices in the 1st quarter valued at about $46,000. Point72 DIFC Ltd purchased a new position in shares of Avid Bioservices in the 2nd quarter valued at about $57,000. Oxford Asset Management LLP purchased a new position in Avid Bioservices during the fourth quarter worth approximately $68,000. Finally, Principal Financial Group Inc. purchased a new position in Avid Bioservices during the second quarter worth approximately $80,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Avid Bioservices Company Profile

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.